Discovery of how SGLT2 inhibitors have unlocked previously unimagined kidney protection is an important step toward advancing therapeutic targets to meet the enormous unmet need for better treatment of patients with DKD. This evidence concerns the gene SLC5A2 and diabetic kidney disease.